Uncategorized
Sun Pharma launches BromSite in US
BromSite for the treatment of postoperative inflammation and prevention of ocular pain is now available in the United States, Sun Pharma announced in a press release.BromSite (bromfenac ophthalmic solution 0.075%) was approved by the FDA on April 8 and is the first NSAID approved to prevent ocular pain and treat eye inflammation after cataract surgery, the release said. It is also the first branded product launched by Sun Pharma in the United States.